The synthetic DNA manufacturer reported 13 straight quarters of growth, driven by higher customer shipments and improved gross margins.
Twist Bioscience posted Q2 2026 revenue of $110.7 million, a 19% increase from $92.8 million in the same period last year. The company attributed the growth to strong demand for its semiconductor-based synthetic DNA products, shipping to 2,583 customers, up from 2,431 in Q2 2025.
Gross margin improved to 51.6% from 49.6% a year earlier, while cost of revenues rose to $53.6 million from $46.8 million. Research and development expenses declined to $19.7 million from $23.9 million in the prior-year quarter.
The company’s operations span the Americas, EMEA, and APAC regions, with continued expansion in its customer base supporting revenue growth.